{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T20:11:49Z","timestamp":1788639109405,"version":"build-2803163510"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Chong-Kun Dang Pharmaceutical Corporation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s13300-026-01898-w","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T05:50:30Z","timestamp":1785217830000},"page":"1355-1367","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of Long-Term Lobeglitazone Treatment on Renal Function and Albuminuria in Korean Patients with Type 2 Diabetes Mellitus: A Multicenter Retrospective Observational Study (LUCKY)"],"prefix":"10.1007","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-8628-7884","authenticated-orcid":false,"given":"Hee-Sung","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4043-2396","authenticated-orcid":false,"given":"Chang Hee","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Hyun","family":"Noh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Jung","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heung-Yong","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In-Kyung","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"issue":"12","key":"1898_CR1","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.2215\/CJN.11491116","volume":"12","author":"RZ Alicic","year":"2017","unstructured":"Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;12(12):2032\u201345.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"1898_CR2","doi-asserted-by":"publisher","first-page":"20","DOI":"10.23876\/j.krcp.23.130","volume":"43","author":"KM Kim","year":"2021","unstructured":"Kim KM, Jeong SA, Ban TH, Hong YA, Hwang SD, Choi SR, et al. Status and trends in epidemiologic characteristics of diabetic end-stage renal disease: an analysis of the 2021 Korean Renal Data System. Kidney Res Clin Pract. 2021;43(1):20\u201332.","journal-title":"Kidney Res Clin Pract"},{"key":"1898_CR3","doi-asserted-by":"publisher","first-page":"15018","DOI":"10.1038\/nrdp.2015.18","volume":"1","author":"MC Thomas","year":"2015","unstructured":"Thomas MC, Brownlee M, Susztak K, Sharma K, Jandeleit-Dahm KA, Zoungas S, et al. Diabetic kidney disease. Nat Rev Dis Primers. 2015;1:15018.","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"1898_CR4","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1053\/j.ajkd.2009.11.013","volume":"55","author":"PA Sarafidis","year":"2010","unstructured":"Sarafidis PA, Stafylas PC, Georgianos PI, Saratzis AN, Lasaridis AN. Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis. Am J Kidney Dis. 2010;55(5):835\u201347.","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"1898_CR5","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.1016\/j.diabres.2015.09.009","volume":"110","author":"SH Kim","year":"2015","unstructured":"Kim SH, Kim SG, Kim DM, Woo JT, Jang HC, Chung CH, et al. Safety and efficacy of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 52 weeks: an open-label extension study. Diabetes Res Clin Pract. 2015;110(3):e27-30.","journal-title":"Diabetes Res Clin Pract"},{"issue":"4","key":"1898_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0092843","volume":"9","author":"SG Kim","year":"2014","unstructured":"Kim SG, Kim DM, Woo JT, Jang HC, Chung CH, Ko KS, et al. Efficacy and safety of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 24-weeks: a multicenter, randomized, double-blind, parallel-group, placebo-controlled trial. PLoS ONE. 2014;9(4):e92843.","journal-title":"PLoS ONE"},{"issue":"10","key":"1898_CR7","doi-asserted-by":"publisher","first-page":"5727","DOI":"10.1111\/dom.16625","volume":"27","author":"EG Hong","year":"2025","unstructured":"Hong EG, Min KW, Chun S, Chung CH, Oh S, Lee CB, et al. Efficacy and safety of lobeglitazone added to metformin and sitagliptin combination therapy in patients with type 2 diabetes: A 52-week, multicentre, randomized, placebo-controlled, phase III clinical trial. Diabetes Obes Metab. 2025;27(10):5727\u201336.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"1898_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-01965-0","volume":"7","author":"W Wang","year":"2017","unstructured":"Wang W, Zhou X, Kwong JSW, Li L, Li Y, Sun X. Efficacy and safety of thiazolidinediones in diabetes patients with renal impairment: a systematic review and meta-analysis. Sci Rep. 2017;7(1):1717.","journal-title":"Sci Rep"},{"issue":"2","key":"1898_CR9","first-page":"185","volume":"30","author":"R Montanes Bermudez","year":"2010","unstructured":"Montanes Bermudez R, Bover Sanjuan J, Oliver Samper A, Ballarin Castan JA, Gracia GS. Assessment of the new CKD-EPI equation to estimate the glomerular filtration rate. Nefrologia. 2010;30(2):185\u201394.","journal-title":"Nefrologia"},{"issue":"1","key":"1898_CR10","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3803\/EnM.2017.32.1.115","volume":"32","author":"KH Bae","year":"2017","unstructured":"Bae KH, Seo JB, Jung YA, Seo HY, Kang SH, Jeon HJ, et al. Lobeglitazone, a novel peroxisome proliferator-activated receptor gamma agonist, attenuates renal fibrosis caused by unilateral ureteral obstruction in mice. Endocrinol Metab (Seoul). 2017;32(1):115\u201323.","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"1","key":"1898_CR11","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.atherosclerosis.2015.08.037","volume":"243","author":"S Lim","year":"2015","unstructured":"Lim S, Lee KS, Lee JE, Park HS, Kim KM, Moon JH, et al. Effect of a new PPAR-gamma agonist, lobeglitazone, on neointimal formation after balloon injury in rats and the development of atherosclerosis. Atherosclerosis. 2015;243(1):107\u201319.","journal-title":"Atherosclerosis"},{"issue":"1","key":"1898_CR12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41598-017-18274-1","volume":"8","author":"JY Jang","year":"2018","unstructured":"Jang JY, Bae H, Lee YJ, Choi YI, Kim HJ, Park SB, et al. Structural basis for the enhanced anti-diabetic efficacy of lobeglitazone on PPARgamma. Sci Rep. 2018;8(1):31.","journal-title":"Sci Rep"},{"issue":"6","key":"1898_CR13","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/dom.12435","volume":"17","author":"SM Jin","year":"2015","unstructured":"Jin SM, Park CY, Cho YM, Ku BJ, Ahn CW, Cha BS, et al. Lobeglitazone and pioglitazone as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, parallel-group, active-controlled, phase III clinical trial with a 28-week extension. Diabetes Obes Metab. 2015;17(6):599\u2013602.","journal-title":"Diabetes Obes Metab"},{"issue":"9493","key":"1898_CR14","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","volume":"366","author":"JA Dormandy","year":"2005","unstructured":"Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone clinical trial in macroVascular events): a randomised controlled trial. Lancet. 2005;366(9493):1279\u201389.","journal-title":"Lancet"},{"issue":"14","key":"1898_CR15","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1056\/NEJMoa1506930","volume":"374","author":"WN Kernan","year":"2016","unstructured":"Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M, et al. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. N Engl J Med. 2016;374(14):1321\u201331.","journal-title":"N Engl J Med"},{"issue":"6","key":"1898_CR16","doi-asserted-by":"publisher","first-page":"855","DOI":"10.4093\/dmj.2021.0264","volume":"46","author":"BY Kim","year":"2022","unstructured":"Kim BY, Kwon HS, Kim SK, Noh JH, Park CY, Park HK, et al. A real-world study of long-term safety and efficacy of lobeglitazone in Korean patients with type 2 diabetes mellitus. Diabetes Metab J. 2022;46(6):855\u201365.","journal-title":"Diabetes Metab J"},{"key":"1898_CR17","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. DIGO 2026 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease [Public Review Draft]. Kidney Int. 2026."},{"issue":"2","key":"1898_CR18","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.clinthera.2020.01.003","volume":"42","author":"K Jang","year":"2020","unstructured":"Jang K, Jeon JY, Moon SJ, Kim MG. Evaluation of the pharmacokinetic interaction between lobeglitazone and dapagliflozin at steady state. Clin Ther. 2020;42(2):295\u2013304.","journal-title":"Clin Ther"},{"issue":"1","key":"1898_CR19","doi-asserted-by":"publisher","first-page":"59","DOI":"10.12793\/tcp.2023.31.e4","volume":"31","author":"H Kim","year":"2023","unstructured":"Kim H, Kim CO, Park H, Park MS, Kim D, Hong T, et al. Evaluation of pharmacokinetic interactions between lobeglitazone, empagliflozin, and metformin in healthy subjects. Transl Clin Pharmacol. 2023;31(1):59\u201368.","journal-title":"Transl Clin Pharmacol"},{"key":"1898_CR20","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.2147\/DDDT.S302215","volume":"15","author":"YK Kim","year":"2021","unstructured":"Kim YK, Hwang JG, Park MK. No relevant pharmacokinetic drug-drug interaction between the sodium-glucose co-transporter-2 inhibitor empagliflozin and lobeglitazone, a peroxisome proliferator-activated receptor-gamma agonist, in healthy subjects. Drug Des Devel Ther. 2021;15:1725\u201334.","journal-title":"Drug Des Devel Ther"},{"issue":"6","key":"1898_CR21","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.clinthera.2020.04.005","volume":"42","author":"SJ Moon","year":"2020","unstructured":"Moon SJ, Yu KS, Kim MG. An assessment of pharmacokinetic interaction between lobeglitazone and sitagliptin after multiple oral administrations in healthy men. Clin Ther. 2020;42(6):1047\u201357.","journal-title":"Clin Ther"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-026-01898-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-026-01898-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-026-01898-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T20:03:13Z","timestamp":1788638593000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-026-01898-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1898"],"URL":"https:\/\/doi.org\/10.1007\/s13300-026-01898-w","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"assertion":[{"value":"19 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Financial interests: This study was supported by a research grant and Rapid Service Fee from Chong Kun Dang Pharmaceutical Co., Ltd. (see Funding section). Beyond this study-related funding, Hee-Sung Kim, Chang Hee Jung, Jung-Hyun Noh, Eun-Jung Rhee, Heung-Yong Jin, and In-Kyung Jeong have nothing further to disclose. Non-financial interests: None.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participating institutions independently obtained approval from their respective Institutional Review Boards prior to study initiation, and the study was conducted in accordance with the ethical standards of the Declaration of Helsinki. The reference numbers of all participating institutional review boards are listed in Supplementary Table\u00a01. The requirement for informed consent was waived by each Institutional Review Board due to the retrospective nature of the study and the use of de-identified clinical data.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}